{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T20:04:32Z","timestamp":1779566672961,"version":"3.53.1"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-183590"],"award-info":[{"award-number":["PJT-183590"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001870","name":"Foundation for Polish Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001870","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011755","name":"National Center for Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011755","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005632","name":"National Centre for Research and Development","doi-asserted-by":"publisher","award":["LIDER\/41\/0206\/L-12\/20\/NCBR\/2021"],"award-info":[{"award-number":["LIDER\/41\/0206\/L-12\/20\/NCBR\/2021"]}],"id":[{"id":"10.13039\/501100005632","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["0066\/L-15\/2024"],"award-info":[{"award-number":["0066\/L-15\/2024"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["05-0007 \/233 \\u2013 FOXM1"],"award-info":[{"award-number":["05-0007 \/233 \\u2013 FOXM1"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ejmech.2025.118532","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T07:18:30Z","timestamp":1766992710000},"page":"118532","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Chemical modification of STL427944 toward morpholine-based 1,3,5-triazines as anticancer agents targeting FOXM1: green synthesis, biological evaluation and ADME-Tox profiling in a colorectal cancer model"],"prefix":"10.1016","volume":"304","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8779-4170","authenticated-orcid":false,"given":"Damian","family":"Ku\u0142aga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Bosak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magda","family":"Ptaszkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Chrzan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Staro\u0144","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamila","family":"Marzec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna K.","family":"Drabczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izabela","family":"Siemie\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Kot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gniewomir","family":"Latacz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Karnafa\u0142","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos A.","family":"Vel\u00e1zquez-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Malarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Mrozek-Wilczkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Boguszewska-Czubara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Greber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzesimir","family":"Ciura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejmech.2025.118532_bib1","first-page":"12","article-title":"Cancer statistics","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118532_bib2","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.annonc.2023.12.003","article-title":"European cancer mortality predictions for the year 2024 with focus on colorectal cancer","volume":"35","author":"Santucci","year":"2024","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.ejmech.2025.118532_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202000363","article-title":"1,3,5-Triazine: a versatile pharmacophore with diverse biological activities","volume":"354","author":"Singh","year":"2021","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.ejmech.2025.118532_bib4","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.3390\/molecules23081956","article-title":"Synthesis of new 1,3,5-Triazine-Based 2-Pyrazolines as potential anticancer agents","volume":"23","author":"Moreno","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.118532_bib5","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.3390\/molecules23071616","article-title":"Hybrid molecules composed of 2,4-Diamino-1,3,5-triazines and 2-Imino-Coumarins and coumarins. Synthesis and cytotoxic properties","volume":"23","author":"Makowska","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.118532_bib6","doi-asserted-by":"crossref","first-page":"5851","DOI":"10.1038\/s41598-017-05934-5","article-title":"Design and discovery of novel monastrol-1,3,5-triazines as potent anti-breast cancer agent via attenuating epidermal growth factor receptor tyrosine kinase","volume":"7","author":"Srivastava","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2025.118532_bib7","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1016\/j.bmcl.2013.06.038","article-title":"Synthesis of novel diarylamino-1,3,5-triazine derivatives as FAK inhibitors with anti-angiogenic activity","volume":"23","author":"Dao","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118532_bib8","article-title":"PI3K\/Akt\/mTOR pathway and its role in cancer therapeutics: are we making headway?","volume":"12","author":"Peng","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2025.118532_bib9","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.3390\/molecules28114278","article-title":"Antitumor activity of s-Triazine derivatives: a systematic review","volume":"28","author":"Dai","year":"2023","journal-title":"Molecules"},{"issue":"8","key":"10.1016\/j.ejmech.2025.118532_bib10","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/jnci\/djj133","article-title":"Antitumor activity of ZSTK474, a new phosphatidylinositol 3-Kinase inhibitor","volume":"98","author":"Yaguchi","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ejmech.2025.118532_bib11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12964-018-0266-6","article-title":"Regulation of the master regulator FOXM1 in cancer","volume":"16","author":"Liao","year":"2018","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.ejmech.2025.118532_bib12","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1007\/s10238-022-00929-7","article-title":"Evaluation of Forkhead BOX M1 (FOXM1) gene expression in colorectal cancer","volume":"23","author":"Rather","year":"2023","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.ejmech.2025.118532_bib13","first-page":"104","article-title":"FOXM1 and its oncogenic signaling in pancreatic cancer pathogenesis","volume":"1845","author":"Huang","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejmech.2025.118532_bib14","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.3390\/cancers13123065","article-title":"FOXM1: a multifunctional oncoprotein and emerging therapeutic target in ovarian cancer","volume":"13","author":"Liu","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2025.118532_bib15","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s10549-017-4207-7","article-title":"FOXM1 transcriptionally regulates expression of integrin \u03b21 in triple-negative breast cancer","volume":"163","author":"Hamurcu","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ejmech.2025.118532_bib16","first-page":"29","article-title":"Prognostic significance of FOXM1 in oral squamous cell carcinoma patients treated by docetaxel-containing regimens","volume":"10","author":"Harada","year":"2019","journal-title":"Mol. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.118532_bib17","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1158\/0008-5472.CAN-16-3566","article-title":"FOXM1 in cancer: interactions and vulnerabilities","volume":"77","author":"Gartel","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118532_bib18","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.semcancer.2022.07.009","article-title":"Dysregulated FOXM1 signaling in the regulation of cancer stem cells","volume":"86","author":"Sher","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ejmech.2025.118532_bib19","article-title":"FoxM1 promotes stemness and radio-resistance of glioblastoma by regulating the master stem cell regulator Sox2","volume":"10","author":"Lee","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2025.118532_bib20","doi-asserted-by":"crossref","first-page":"5658","DOI":"10.1158\/0008-5472.CAN-12-0953","article-title":"FoxM1 and Wnt\/\u03b2-Catenin signaling in glioma stem cells","volume":"72","author":"Gong","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118532_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112902","article-title":"SP1-independent inhibition of FOXM1 by modified thiazolidinediones","volume":"209","author":"Tabatabaei Dakhili","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118532_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2023.189015","article-title":"Small-molecule inhibitors targeting FOXM1: current challenges and future perspectives in cancer treatments","volume":"1878","author":"Raghuwanshi","year":"2023","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.ejmech.2025.118532_bib23","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/s41419-021-03978-0","article-title":"Novel FOXM1 inhibitor identified via gene network analysis induces autophagic FOXM1 degradation to overcome chemoresistance of human cancer cells","volume":"12","author":"Borhani S","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2025.118532_bib24","article-title":"Dual effect of tryptamine on prostate cancer cell growth regulation: a pilot study","volume":"23","author":"Li","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.118532_bib25","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1016\/j.bmcl.2016.06.055","article-title":"Design, synthesis and anticancer activity of novel hybrid compounds between benzofuran and N-aryl piperazine","volume":"26","author":"Mao","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118532_bib26","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.3390\/molecules22111857","article-title":"Synthesis and antitumor activity of novel arylpiperazine derivatives containing the saccharin moiety","volume":"22","author":"Chen","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.118532_bib27","doi-asserted-by":"crossref","first-page":"12048","DOI":"10.3390\/molecules190812048","article-title":"Synthesis and cytotoxic activity evaluation of novel arylpiperazine derivatives on human prostate cancer cell lines","volume":"19","author":"Chen","year":"2014","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.118532_bib28","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00706-021-02830-7","article-title":"Synthesis, characterization, and biological evaluations of substituted phenethylamine-based urea as anticancer and antioxidant agents","volume":"152","author":"\u00d6zgeri\u015f","year":"2021","journal-title":"Monatsh. Chem."},{"key":"10.1016\/j.ejmech.2025.118532_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ultsonch.2024.106951","article-title":"Green synthesis of 1,3,5-triazine derivatives using a sonochemical protocol","volume":"108","author":"Ku\u0142aga","year":"2024","journal-title":"Ultrason. Sonochem."},{"key":"10.1016\/j.ejmech.2025.118532_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.117995","article-title":"Discovery of new dual butyrylcholinesterase (BuChE) inhibitors and 5-HT7 receptor antagonists as compounds used to treat Alzheimer's disease symptoms","volume":"186","author":"Ku\u0142aga","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2025.118532_bib31","article-title":"DOZN TM2.0: a quantitative green chemistry evaluator for a sustainable future","volume":"970\u2013971","author":"Sharma","year":"2022","journal-title":"J. Organomet. Chem."},{"key":"10.1016\/j.ejmech.2025.118532_bib32","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1016\/j.bmcl.2004.06.008","article-title":"Aminotriazine 5-HT7 antagonists","volume":"14","author":"Mattson","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118532_bib33","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1038\/nprot.2006.339","article-title":"Clonogenic assay of cells in vitro","volume":"1","author":"Franken","year":"2006","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ejmech.2025.118532_bib34","doi-asserted-by":"crossref","first-page":"537","DOI":"10.4161\/cbt.24349","article-title":"Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines","volume":"14","author":"Pierce","year":"2013","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ejmech.2025.118532_bib35","article-title":"Optimized scratch assay for in vitro testing of cell migration with an automated optical camera","volume":"138","author":"Vang Mouritzen","year":"2018","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.ejmech.2025.118532_bib36","doi-asserted-by":"crossref","DOI":"10.1098\/rsif.2018.0709","article-title":"In vitro cell migration quantification method for scratch assays","volume":"16","author":"Bobadilla","year":"2019","journal-title":"J. R. Soc. Interface"},{"key":"10.1016\/j.ejmech.2025.118532_bib37","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.2174\/1568026615666150915115823","article-title":"Advances in the development of class I phosphoinositide 3-Kinase (PI3K) inhibitors","volume":"16","author":"Sabbah","year":"2016","journal-title":"Curr. Top Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118532_bib38","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ejca.2011.09.006","article-title":"The catalytic phosphoinositol 3-kinase isoform p110\u03b4 is required for glioma cell migration and invasion","volume":"48","author":"Luk","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejmech.2025.118532_bib39","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s41586-022-04685-2","article-title":"Intermittent PI3K\u03b4 inhibition sustains anti-tumour immunity and curbs irAEs","volume":"605","author":"Eschweiler","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.118532_bib40","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3390\/biom13050857","article-title":"FOXM1: functional roles of FOXM1 in non-malignant diseases","volume":"13","author":"Zhang","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejmech.2025.118532_bib41","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/ncb1217","article-title":"FoxM1 is required for execution of the mitotic programme and chromosome stability","volume":"7","author":"Laoukili","year":"2005","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.118532_bib42","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/978-1-4615-4253-7_10","article-title":"Cell cycle regulation by the Cdc25 phosphatase family","volume":"4","author":"Nilsson","year":"2000","journal-title":"Prog. Cell Cycle Res."},{"key":"10.1016\/j.ejmech.2025.118532_bib43","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1517\/14728222.12.6.663","article-title":"FoxM1 inhibitors as potential anticancer drugs","volume":"12","author":"Gartel","year":"2008","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ejmech.2025.118532_bib44","doi-asserted-by":"crossref","first-page":"9857","DOI":"10.2147\/CMAR.S270825","article-title":"FoxM1 is upregulated in osteosarcoma and inhibition of FoxM1 decreases osteosarcoma cell proliferation, migration, and invasion","volume":"12","author":"Zhu","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.ejmech.2025.118532_bib45","doi-asserted-by":"crossref","first-page":"33403","DOI":"10.18632\/oncotarget.23607","article-title":"Cancer stem cells in progression of colorectal cancer","volume":"9","author":"Zhou","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2025.118532_bib46","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40164-024-00474-x","article-title":"Crosstalk between colorectal CSCs and immune cells in tumorigenesis, and strategies for targeting colorectal CSCs","volume":"13","author":"Zhao","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2025.118532_bib47","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.3748\/wjg.v19.i17.2603","article-title":"CD133: a cancer stem cells marker, is used in colorectal cancers","volume":"19","author":"Ren","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ejmech.2025.118532_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143513","article-title":"Lgr5 methylation in cancer stem cell differentiation and prognosis-prediction in colorectal cancer","volume":"10","author":"Su","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2025.118532_bib49","doi-asserted-by":"crossref","first-page":"bio041673","DOI":"10.1242\/bio.041673","article-title":"Surface expression marker profile in colon cancer cell lines and sphere-derived cells suggests complexity in CD26+ cancer stem cells subsets","volume":"8","author":"V\u00e1zquez-Iglesias","year":"2019","journal-title":"Biol. Open"},{"key":"10.1016\/j.ejmech.2025.118532_bib50","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.3390\/ijms22041603","article-title":"Portrait of cancer stem cells on colorectal cancer: molecular biomarkers, signaling pathways and miRNAome","volume":"22","author":"Angius","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.118532_bib51","doi-asserted-by":"crossref","first-page":"71","DOI":"10.5599\/admet.559","article-title":"Chromatographic technique to support ADMET&DMPK in early drug discovery","volume":"6","author":"Valko","year":"2018","journal-title":"ADMET DMPK"},{"key":"10.1016\/j.ejmech.2025.118532_bib52","doi-asserted-by":"crossref","first-page":"74","DOI":"10.5599\/admet.530","article-title":"The role and impact of high throughput biomimetic measurements in drug discovery","volume":"6","author":"Young","year":"2018","journal-title":"ADMET DMPK"},{"key":"10.1016\/j.ejmech.2025.118532_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2023.464549","article-title":"Modeling of small molecule's affinity to phospholipids using IAM-HPLC and QSRR approach enhanced by similarity-based machine algorithms","volume":"1714","author":"Ciura","year":"2024","journal-title":"J. Chromatogr. A."},{"key":"10.1016\/j.ejmech.2025.118532_bib54","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jpba.2011.11.033","article-title":"Chromatography approaches for early screening of the phospholipidosis-inducing potential of pharmaceuticals","volume":"61","author":"Jiang","year":"2012","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejmech.2025.118532_bib55","first-page":"191","article-title":"Prediction of hERG inhibition of drug discovery compounds using biomimetic HPLC measurements","volume":"9","author":"Stergiopoulos","year":"2021","journal-title":"ADMET DMPK"},{"key":"10.1016\/j.ejmech.2025.118532_bib56","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jpba.2016.04.009","article-title":"Lipophilicity and biomimetic properties measured by HPLC to support drug discovery","volume":"130","author":"Valk\u00f3","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejmech.2025.118532_bib57","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1007\/s11095-007-9517-8","article-title":"A novel design of artificial membrane for improving the PAMPA model","volume":"25","author":"Chen","year":"2008","journal-title":"Pharm. Res."}],"updated-by":[{"DOI":"10.1016\/j.ejmech.2026.118933","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000}},{"DOI":"10.1016\/j.ejmech.2026.118933","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000}}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425012978?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425012978?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T19:16:28Z","timestamp":1779563788000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425012978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":57,"alternative-id":["S0223523425012978"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118532","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemical modification of STL427944 toward morpholine-based 1,3,5-triazines as anticancer agents targeting FOXM1: green synthesis, biological evaluation and ADME-Tox profiling in a colorectal cancer model","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118532","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118532"}}